MRK•benzinga•May 15, 2025 at 10:47 AM

Merck's Keytruda Phase 3 KEYNOTE-B96 Trial (Also Known As ENGOT-ov65) Met Its Primary Endpoint Of Progression-free Survival For Patients With Platinum-resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 And In All Comers

No summary available.

Read the full article from the original source for complete details and context.

Article published on May 15, 2025 by benzinga